SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump Says Anthropic No Longer Seen as National Security Threat 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
 to Ring the Nasdaq Stock Market Opening Bell on January 11 - EconoTimes)
New York, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Oasmia Pharmaceutical AB (Nasdaq:OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced that the Company will ring the Nasdaq Opening Bell on Monday, January 11 in honor of its recent listing on the Nasdaq Capital Market.
"On behalf of the entire Oasmia team, we are honored and appreciative of the opportunity to ring the Nasdaq Opening Bell," said Julian Aleksov, Executive Chairman of Oasmia. "We believe the human and animal oncology treatments we have brought to market, as well as the next-generation technologies we continue to develop, will have a profound impact on the treatment of various cancers for both patients and physicians. With our recently established US sales and marketing platform, we are confident in the continued adoption of our family of products, making us well-positioned for future growth and recognition among US security-holders."
A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live - The ceremony will begin at approximately 9:20am EST.
The Company began trading on the Nasdaq Capital Market on October 23, 2015.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on Nasdaq Stockholm (OASM.ST), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and Nasdaq Capital Market (OASM.US).
Julian Aleksov, Executive Chairman
Tel: +46 18 50 54 40
E-mail: [email protected]
For media relations:
Eric Fischgrund
Founder FischTank
Tel: +1 (646) 699 1414
E-mail: [email protected]
For investor relations:
Robert Haag
Managing Partner
IRTH Communications
Tel: +1 (866) 976 4784
E-mail: [email protected]
